Common medications that increase the risk for developing community-acquired pneumonia

Current Opinion in Infectious Diseases

Volumn 23, Issue 2, 2010, Pages 145-151

  Restrepo, Marcos I ^a,b   Mortensen, Eric M ^a,b   Anzueto, Antonio ^b  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Glucocorticoids; Histamine H2 receptor antagonists; Outcome assessment (healthcare); Pneumonia; Proton pump inhibitors

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CORTICOSTEROID THERAPY; HEALTH CARE COST; HUMAN; INFECTION RISK; MORTALITY; PATIENT MONITORING; REVIEW; RISK BENEFIT ANALYSIS;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; COMMUNITY-ACQUIRED INFECTIONS; HISTAMINE H2 ANTAGONISTS; HUMANS; PNEUMONIA; PROTON PUMP INHIBITORS; RISK;

EID: 77649245480     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328336eac1     Document Type: Review

References (70)

1. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005; 294:1255-1259.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349:1498-1504.
3. Heron M, Hoyert DL, Murphy SL, et al. Deaths: final data for 2006. Natl Vital Stat Rep 2009; 57:1-134.
4. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-789.
5. Janssens JP, Krause KH. Pneumonia in the very old. Lancet Infect Dis 2004; 4:112-124.
6. Kaplan V, Angus DC, Griffin MF, et al. Hospitalized community-acquired pneumonia in the elderly: age-and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med 2002; 165:766-772.
7. Fine MJ, Smith MA, Carson CA, etal. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275:134-141.
8. Hoyert DL, Kung HC, Smith BL. Deaths: preliminary data for 2003. Natl Vital Stat Rep 2005; 53:1-48.
9. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004; 39:1642-1650.
10. Kothe H, Bauer T, Marre R, et al. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J 2008; 32:139-146.
11. Kaplan V, Clermont G, Griffin MF, etal. Pneumonia: still the old man's friend? Arch Intern Med 2003; 163:317-323.
12. National Heart Lung and Blood Institute. Morbidity & mortality: 2002 chart book on cardiovascular, lung, and blood diseases. Bethesda: U.S. Department of Health and Human Services, National Institutes of Health, 2002.
13. Mannino DM, Homa DM, Akinbami LJ, etal. Chronic obstructive pulmonary disease surveillance: United States, 1971-2000. MMWR Surveill Summ 2002; 51:1-16.
14. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176:532-555.
15. Chatila WM, Thomashow BM, Minai OA, et al. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5:549-555.
16. Lange P, Vestbo J, Nyboe J. Risk factors for death and hospitalization from pneumonia. A prospective study of a general population. Eur Respir J 1995; 8:1 694-1698.
17. Sliedrecht A, den Elzen WP, VerheijTJ, etal. Incidence and predictive factors of lower respiratory tract infections among the very elderly in the general population. The Leiden 85-plus Study. Thorax 2008; 63:817-822.
18. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166:333-339.
19. Jansen HM, Sachs AP, van Alphen L. Predisposing conditions to bacterial infections in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151:2073-2080.
20. Fine MJ, AubleTE, Yealy DM, etal. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-250.
21. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006; 28:346-351.
22. Rello J, Rodriguez A, Torres A, etal. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006; 27:1210-1216.
23. Torres A, Menendez R. Mortality in COPD patients with community-acquired pneumonia: who is the third partner? Eur Respir J 2006; 28:262-263. (Pubitemid 44914222)
24. Pifarre R, Falguera M, Vicente-de-Vera C, Nogues A. Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Respir Med 2007; 101:2139-2144.
25. Molinos L, Clemente MG, Miranda B, etal. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect 2009; 58:417-424.
26. Marrie TJ, Huang JQ. Low-risk patients admitted with community-acquired pneumonia. Am J Med 2005; 118:1357-1363.
27. Rello J, Rodriguez A, Lisboa T, et al. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med 2009; 37:456-462.
28. Pauwels RA, Lofdahl CG, Laitinen LA, etal. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340:1948-1953.
29. Burge PS, Calverley PM, Jones PW, etal. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297-1303.
30. Vestbo J, Sorensen T, Lange P, etal. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353:181 9-1823.
31. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343:1902-1909.
32. Mahler DA, Wire P, Horstman D, etal. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:1084-1091.
33. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21:74-81.
34. Calverley P, Pauwels R, Vestbo J, etal. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 36:449-456.
35. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22:912-919.
36. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/flutica-sone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:144-149.
37. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146:545-555.
38. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone pro pionate or tiotropium bromide. Am J RespirCrit Care Med 2008; 177:19-26.
39. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374:712-719.
40. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173:842-846.
41. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009; 34:13-16.
42. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patientsreceiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009; 34:641-647.
43. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Manage ment of Community-Acquired Pneumonia in Adults. Clin Infect Dis 2007; 44:S27-S72.
44. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300:2407-2416.
45. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009; 169:219-229.
46. Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs. long-acting betaagonists monotherapy for stable COPD: a systematic review. Chest 2009; 136:1029-1038.
47. WelteT. Acute exacerbation of chronic obstructive pulmonary disease: more a functional than an inflammatory problem? Am J Respir Crit Care Med 2008; 177:130-131.
48. Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008; 68:1975-2000.
49. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009; 69:549-565.
50. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176:162-166.
51. Berson W, Adriani J. Silent regurgitation and aspiration during anesthesia. Anesthesiology 1954; 15:644-649.
52. Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001; 344:665-671.
53. Jones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. BMJ 1989; 298:30-32.
54. van Bommel MJ, Numans ME, de Wit NJ, Stalman WA. Consultations and referrals for dyspepsia in general practice: a one year database survey. Postgrad Med J 2001; 77:514-518.
55. Martin RM, Lim AG, Kerry SM, Hilton SR. Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care. Aliment Pharmacol Ther 1998; 12:797-805.
56. Howden CW, Hunt RH. Relationship between gastric secretion and infection. Gut 1987; 28:96-107.
57. Giannella RA, Broitman SA, Zamcheck N. Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective. Ann Intern Med 1973; 78:271-276.
58. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294:2989-2995.
59. Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004; 171:33-38.
60. Lowe DO, Mamdani MM, Kopp A, et al. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis 2006; 43:1272-1276.
61. Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008; 103:2308-2313.
62. Prod'hom G, Leuenberger P, Koerfer J, et al. Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer. A randomized controlled trial. Ann Intern Med 1994; 120:653-662.
63. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA 1996; 275:308-314.
64. Messori A, Trippoli S, Vaiani M, et al. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. BMJ 2000; 321:1103-1106.
65. Kantorova I, Svoboda P, Scheer P, et al. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepatogastroenterology 2004; 51:757-761.
66. Apte NM, Karnad DR, MedhekarTP, et al. Gastric colonization and pneumonia in intubated critically ill patients receiving stress ulcer prophylaxis: a randomized, controlled trial. Crit Care Med 1992; 20:590-593.
67. Driks MR, Craven DE, Celli BR, et al. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization. N Engl J Med 1987; 317:1376-1382.
68. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 1955-1960.
69. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167:950-955.
70. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149:391-398.